UNSPSC 51101613: Pentamidine

This classification denotes an antiprotozoal agent and antifungal with the molecular formula C19H24N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 673LC5J4LQ, chemically known as 4,4-(pentamethylenedioxy)dibenzamidine but generally known as pentamidine, which bears US NIH Compound Identifier 4735. European Medicines Agency schedules Pentamidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09682MIG. The term PENTAMIDINE is an International Non-Proprietary Name.

UNSPSC 51101613 Pentamidine is a Commodity code representing pharmaceutical products procured by state and local health agencies. However, the recent state and local opportunities tagged under this code do not reflect pentamidine procurement. The Illinois Department of Public Health's August 2026 piggyback pharmaceutical award through MMCAP Infuse to Chartwell Rx LLC covered antibiotic tablets (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg) with a total contract value of $2,999,999.11 over 12 months plus two renewal options. Seminole County, Florida's June 2026 IFB solicitation sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford. Neither opportunity involves pentamidine or related antimicrobial agents typically associated with the code's nominal scope. The issuing bodies are state health departments and county health agencies using cooperative purchasing vehicles and competitive bidding processes.

The code shows activity in Illinois and Florida, though the opportunities available do not substantiate current pentamidine procurement at the state and local level. The Illinois contract was completed on an IFB basis with Chartwell Rx LLC as the awarded vendor; Seminole County's IFB closed on July 26, 2023, with electronic bid submission required through the county e-Procurement Portal and FEMA compliance requirements noted. The mismatch between the code name and the actual pharmaceutical products in recent opportunities suggests this code may not be the primary or accurate classification for active state and local pharmaceutical procurement in the current market.